Investigational New Drug application for Uricase-PEG 20 approved

NewsGuard 100/100 Score

EnzymeRx, LLC, a clinical-stage biotechnology company, announced that its Investigational New Drug (IND) application for Uricase-PEG 20, filed with the U.S. Food and Drug Administration (FDA) last month, has become effective.

EnzymeRx filed this IND for intravenous Uricase-PEG 20 in the management of elevated uric acid levels associated with tumor lysis syndrome. Tumor lysis syndrome is a serious condition that can occur during the treatment of certain tumors, and can result in sharply elevated uric acid levels. Uricase-PEG 20 metabolizes poorly soluble uric acid into highly soluble allantoin, and in a prior phase 1 clinical trial, it was shown to lower uric acid levels in gout patients. Because its long half-life may provide for an extended duration of uric acid-lowering after just a single dose, Uricase-PEG 20 may offer a convenient alternative to existing therapies for tumor lysis syndrome. EnzymeRx plans to launch a dose-ranging phase 1 clinical trial of intravenous Uricase-PEG 20 shortly.

Tony Fiorino, MD, PhD, President and Chief Executive Officer of EnzymeRx, remarked: “We are pleased with the FDA’s review of the IND, which allows us begin the clinical development of intravenous Uricase-PEG 20. Our near-term plans include not only launching the intravenous phase 1 study, but also resuming the clinical development of intramuscular Uricase-PEG 20 in gout. The EnzymeRx team is looking forward to a busy fourth quarter.”


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Innovative CAR T cell therapy targets two proteins to combat aggressive brain tumor growth